Concord Drugs quarterly results and financials

Concord Drugs (BSE 538965)₹72.72+2.19%(9 Nov 2026 close)Pharmaceuticals

Key facts

In the Jun 2026 quarter (consolidated), Concord Drugs reported sales of ₹21.01 Cr, up 53.9% from Jun 2025, and net profit of ₹1.10 Cr, up 900.0% year on year. For the year to Mar 2026, sales were ₹78.99 Cr and net profit ₹1.05 Cr.

Sales (Jun 2026): ₹21.01 Cr
Net profit (Jun 2026): ₹1.10 Cr
Sales (FY Mar 2026): ₹78.99 Cr
Net profit (FY Mar 2026): ₹1.05 Cr
EPS (Jun 2026): ₹0.85
Borrowings (Mar 2026): ₹13.59 Cr

Company filings, consolidated accounts; latest reported quarter Jun 2026

Concord Drugs quarterly results

₹ crore unless stated; each column is a quarter.

Concord Drugs Quarterly results
	Sep 2023	Dec 2023	Mar 2024	Jun 2024	Sep 2024	Dec 2024	Mar 2025	Jun 2025	Sep 2025	Dec 2025	Mar 2026	Jun 2026
Sales	7.55	12.82	15.68	11.73	12.41	10.83	10.42	13.65	10.31	17.04	38.01	21.01
Expenses	5.90	12.12	15.24	10.84	11.46	9.38	9.32	12.56	9.16	16.00	36.33	18.61
Operating Profit	1.61	0.62	0.34	0.82	0.87	1.39	1.04	1.01	1.09	0.93	1.49	2.28
OPM %	21.5%	4.9%	2.2%	7.1%	7.1%	12.9%	10.1%	7.5%	10.7%	5.5%	4.0%	10.9%
Other Income	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Interest	0.44	0.51	0.51	0.46	0.48	0.51	0.62	0.50	0.50	0.35	0.41	0.41
Depreciation	0.38	0.38	0.38	0.33	0.33	0.36	0.37	0.36	0.33	0.30	0.34	0.34
Profit before tax	0.81	−0.27	−0.55	0.05	0.08	0.54	0.07	0.17	0.28	0.30	0.76	1.55
Tax %	29.9%	−3.9%	−39.0%	49.9%	42.8%	58.4%	33.3%	25.0%	29.6%	27.6%	29.3%	27.9%
Net Profit	0.55	−0.23	−0.33	0.02	0.03	0.22	0.03	0.11	0.18	0.21	0.52	1.10
EPS (Rs)	0.61	−0.25	−0.35	0.04	0.05	0.24	0.05	0.13	0.20	0.18	0.41	0.85

Concord Drugs profit and loss

₹ crore unless stated; years end in March. TTM is the last four quarters.

Concord Drugs Profit and loss
	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026	TTM
Sales	59.12	52.21	45.03	45.35	78.99	86.37
Expenses	53.20	47.35	40.75	41.00	74.09	80.10
Operating Profit	5.58	4.56	4.03	4.13	4.54	5.79
OPM %	9.5%	8.8%	9.0%	9.1%	5.8%	6.7%
Other Income	0.11	0.02	0.02	0.02	0.00	0.00
Interest	1.69	1.72	1.88	2.04	1.72	1.67
Depreciation	1.75	1.62	1.55	1.42	1.36	1.31
Profit before tax	2.26	1.25	0.63	0.70	1.48	2.89
Tax %	28.8%	20.9%	25.7%	50.7%	28.5%	—
Net Profit	1.58	0.98	0.46	0.33	1.05	2.01
EPS (Rs)	1.83	1.07	0.48	0.35	0.81	1.64
Dividend payout %	0.0%	0.0%	0.0%	0.0%	0.0%	—

Concord Drugs balance sheet

₹ crore, at each year end.

Concord Drugs Balance sheet
	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Equity Capital	8.72	9.30	9.97	9.97	13.15
Reserves	19.59	22.34	23.78	24.06	35.28
Borrowings	16.44	16.96	17.51	19.21	13.59
Other Liabilities	11.60	9.53	7.43	11.75	12.71
Total Liabilities	56.35	58.13	58.69	64.99	74.73
Fixed Assets	13.95	12.90	11.67	12.19	11.57
CWIP	0.56	0.93	1.62	2.01	2.44
Investments	0.00	0.90	0.85	0.81	0.79
Other Assets	41.84	43.40	44.55	49.98	59.93
Inventories	17.50	20.07	22.94	25.28	25.53
Trade receivables	22.76	15.76	12.68	13.55	24.28
Cash & equivalents	0.06	0.09	0.17	0.22	0.74
Total Assets	56.35	58.13	58.69	64.99	74.73

Concord Drugs cash flow

₹ crore, for each year.

Concord Drugs Cash flow
	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Cash from operating activity	0.76	1.65	0.78	3.71	−6.75
Cash from investing activity	−2.45	−2.28	−1.02	−2.33	−1.14
Cash from financing activity	1.67	0.61	0.27	−1.42	8.04
Net cash flow	0.00	0.01	0.06	−0.01	0.15
Capex	2.45	0.85	1.01	2.32	1.16
Free cash flow	−1.70	0.79	−0.22	1.38	−7.95
CFO / OP %	26.1%	45.1%	25.0%	95.1%	−139.9%

Concord Drugs ratios

Working-capital days and returns, by year.

Concord Drugs Ratios
	Mar 2022	Mar 2023	Mar 2024	Mar 2025	Mar 2026
Debtor days	142	111	103	110	113
Inventory days	153	180	253	263	139
Days payable	62	47	34	79	38
Cash conversion cycle	230	241	320	292	212
Working capital days	112	152	133	116	146
ROCE %	—	6.3%	5.0%	5.2%	5.5%

Concord Drugs: frequently asked questions

What are the latest quarterly results of Concord Drugs?

For the Jun 2026 quarter, Concord Drugs reported sales of ₹21.01 Cr, up 53.9% year on year and net profit of ₹1.10 Cr, up 900.0% year on year. The operating margin was 10.9%.

What is the annual revenue of Concord Drugs?

Concord Drugs' sales for the year to Mar 2026 were ₹78.99 Cr; over the last twelve months they were ₹86.37 Cr.

What is the net profit of Concord Drugs?

Net profit for the year to Mar 2026 was ₹1.05 Cr, and ₹2.01 Cr over the last twelve months. Earnings per share over the same trailing period were ₹1.64.

How much debt does Concord Drugs have?

Concord Drugs reported borrowings of ₹13.59 Cr at Mar 2026, against cash and equivalents of ₹0.74 Cr.

What is the free cash flow of Concord Drugs?

Cash from operations was −₹6.75 Cr in the year to Mar 2026; after capital spending, free cash flow was −₹7.95 Cr.

Loading…